The impact of social protection interventions on treatment and socioeconomic outcomes of tuberculosis-affected people and households in low income, high burden settings: A systematic review and meta-analysis Authors: Mollie Hudson, Heather Todd, Talemwa Nalugwa, Ann Schraufnagel, Canice Christian, Delia Boccia, Tom Wingfield, Priya B. Shete, Graeme Hoddinott, Graeme Hoddinott, Graeme Hoddinott Published: 2026 ABSTRACT Tuberculosis (TB) is the leading cause of death due to infectious disease worldwide. Social protection interventions can benefit TB-affected households. We conducted a systematic review and meta-analysis to quantify the effectiveness of social protection on TB treatment and socioeconomic outcomes. We identified articles published from January 2012 to December 2025 by searching PubMed (includes MEDLINE), Embase, and Web of Science. We included studies that described at least one social protection intervention and reported on either TB treatment or socioeconomic outcomes for people with TB or TB-affected households. Random-effects meta-analysis was used for our primary outcome of interest, TB treatment success (treatment completion or cure). We performed a meta-regression to evaluate the association of study characteristics with odds of TB treatment success. Risk of bias was assessed using the Newcastle Ottawa Scale and the Cochrane Risk of Bias tool. This review was registered prospectively in the PROSPERO database (registration number CRD42022382181). Our search generated 55,975 articles. Of the 55 which were eligible for inclusion, 41 reported TB treatment outcomes, 8 reported on socioeconomic outcomes, and two studies reported both TB treatment and socioeconomic outcomes. Random-effects meta-analysis of 26 articles found that people with TB who received social protection interventions during treatment had 2.15 times the odds of TB treatment success (95% CI 1.76, 2.64, I2 94.5%). Subgroup analysis indicated that whether a social protection intervention was TB sensitive or TB specific was a significant source of heterogeneity, although both increased the odds of TB treatment success. Both TB sensitive and TB specific social protection interventions significantly improve odds of TB treatment success. Outcomes and definitions used in our study have the potential to guide further research and implementation of social protection for TB-affected populations. Introduction Tuberculosis (TB) is one of the leading causes of infectious disease deaths worldwide. Despite effective and widely available treatment, an estimated 10.7 million people were infected with TB and 1.23 million people died from TB in 2024 [1]. TB-affected individuals are often trapped in a vicious cycle of poverty; impoverished individuals often have risk factors that make them more susceptible to TB (e.g., crowded living conditions, poor access to care, malnutrition), and becoming ill with TB often precipitates devastating economic consequences incurred from the such as costs associated with of care-seeking and treatment and lost wages due to missed work [2,3]. TB-affected households often use negative financial coping strategies and experience catastrophic costs, defined as total costs in excess of 20% of the annual household income [4]. To break out of the cycle of poverty and disease, interventions are urgently needed that address both underlying social and economic determinants and vulnerabilities of TB-affected individuals. Social protection interventions, broadly defined by the World Bank as systems that “help the poor and vulnerable cope with crisis and shocks, invest in the health and education of their children, and protect the aging population,” [5] are such a strategy. Social protection interventions are a key pillar of the World Health Organization (WHO) End TB Strategy, the United Nations’ Sustainable Development Goals (SDGs), and the UN Declaration on TB [6–8]. These interventions include cash transfers to eligible populations, job training programs to support income generation, and nutritional or food security programs. When implemented effectively, social protection can decrease TB incidence, improve TB treatment outcomes, and improve socioeconomic outcomes [3,9,10]. While prior studies, including some systematic reviews, have found that social protection interventions can improve TB treatment outcomes, [11] they were limited in their ability to widely inform policy and programmatic implementation of various types of social protections in a wide array of settings. De Andrade et al., for example, limited their meta-analysis to randomized control trials [12]. While high quality, these results exclude a substantial body of evidence generated by high quality observational studies on a range of TB treatment outcomes. Another study conducted by Richterman et al. focused only on cash transfers, thereby not including studies that describe other types of social protection interventions such as food assistance or psychosocial support.11 No systematic review has described the impact of social protection interventions on socioeconomic outcomes, including catastrophic costs, dissaving, or standardized measures of poverty. The objective of this systematic review and meta-analysis is to provide synthesized evidence of health and socioeconomic effectiveness of social protection interventions for TB-affected individuals and households required to inform global scale-up of these strategies. Methods Our systematic review and meta-analysis were conducted in accordance with PRISMA guidelines. Specifically, we 1) iteratively developed a list of search terms and a search strategy, 2) searched for relevant articles in a pre-determined number of databases, 3) systematically screened titles and abstracts for potentially eligible articles, 4) read the full text of articles deemed eligible for full text review, 5) agreed upon articles that met criteria for inclusion, 6) extracted relevant data from each study, 7) conducted quality and risk of bias assessments, and 8) synthesized available evidence. We used the Population, Intervention, Comparison, Outcome, and Time (PICOT) format to define our research questions for this systematic review and meta-analysis (S1 Text): Do people with TB who have enrolled in at least one social protection intervention demonstrate an improvement in TB treatment success (treatment completion or cure) compared to people with TB who have not enrolled in and/or been recipients of social protection interventions? Do people with TB who have enrolled in at least one social protection intervention demonstrate an improvement in TB treatment success (treatment completion or cure) compared to people with TB who have not enrolled in and/or been recipients of social protection interventions? Do people with TB who have enrolled in at least one social protection intervention have better socioeconomic outcomes, including lower rates of catastrophic costs and dissaving, compared to people with TB who have not enrolled in and/or been recipients of social protection interventions? Do people with TB who have enrolled in at least one social protection intervention have better socioeconomic outcomes, including lower rates of catastrophic costs and dissaving, compared to people with TB who have not enrolled in and/or been recipients of social protection interventions? This systematic review protocol was guided by the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) protocol checklist [13]. A scoping review [14] was also conducted to landscape the available evidence and to inform the protocol for this analysis, which has been published previously [15]. Search strategy and selection criteria Our initial search was conducted March 2021, and then repeated September 2023, January 2025, and December 2025 to include articles published through December 2025. We included three electronic databases: PubMed (includes MEDLINE), Embase, and Web of Science. We used Google Scholar Advanced to search selected, relevant databases, explained in detail in our scoping review [14]. Articles were imported into Covidence [16] for systematic screening by the study team (S2 Text) in accordance with PRISMA guidelines. Articles deemed eligible for inclusion were reviewed by four researchers (MH, HT, AS and CC; S2 Text). We included randomized controlled trials, cross-sectional studies and cohort studies. Studies were included if they described people with pulmonary and extra pulmonary TB, people with drug-sensitive (DS-TB) and drug-resistant (DR-TB)/multi-drug resistant TB (MDR-TB), people either with or without HIV-TB co-infection, or TB-affected households in either low-to-middle-income countries (LMICs) and/or high burden TB countries as defined by WHO or the World Bank [1,17]. We only included studies published since 2012, which coincided with the “World Bank’s Social Protection and Labour Strategy 2012-2022,” [18] which supported initiatives on reducing socioeconomic risk, after which definitions of social protection were expected to be uniform. We did not restrict our search by language. Intervention We only included studies in which the main independent variable was enrollment in, and/or receipt of, a social protection intervention as defined by the World Bank [5]. We included social protection interventions specifically designed for individuals or households affected by TB (TB-specific social protection interventions), for which microbiologic or clinical diagnosis of TB is a requirement of eligibility for the social protection intervention, as well as social protection interventions designed for individuals or households inclusive of those affected by TB but identified as eligible based on non-TB criteria (TB-sensitive social protection interventions) [19]. We excluded interventions that were not intended to reduce socioeconomic risk; for example, nutritional support as a clinical intervention during a hospitalization was not considered to be social protection, and studies describing these types of intervention were not included. Outcomes We only included studies for which the main dependent variable was at least one standardized outcome related to TB treatment including cure, treatment completion, treatment success (a composite variable of TB cure and treatment completion) mortality/death, treatment default, loss to follow up, [1] and/or at least one standardized socioeconomic outcome such as catastrophic costs, dissaving or impoverishment, in accordance with global definitions [1]. Screening and descriptive analysis Titles and abstracts were systematically and independently screened by the study team (S2 Text). Potentially eligible articles underwent full text review. Questions about study inclusion were discussed by reviewers (MH, HT) with adjudication by a third reviewer (TN) or senior researchers (TW, PBS). Fig 1 describes the search process in accordance with PRISMA protocols for systematic reviews. Flow diagram of search process to identify eligible studies using PRISMA. Quantitative analysis Three reviewers (MH, AS, CC) independently extracted quantitative data reported in eligible papers (S1-S4 Tables). For the meta-analysis, authors extracted data describing the number or percent of individuals who attained TB treatment success in both the treatment (receipt of social protection in conjunction with standard biomedical treatment) and the control (standard biomedical treatment only) groups. All estimates of effect for dichotomous outcomes (e.g., “achieved treatment success” versus “did not achieve treatment success”) were reported as odds ratios with a 95% confidence interval. We used a random effects model [20] for our meta-analysis to account for heterogeneity between studies. For our subgroup analyses, authors extracted data describing type of social protection intervention, study setting, WHO region, and whether an intervention was considered TB sensitive or TB specific. All calculations were conducted in STATA SE version 19 [21]. A logistic meta-regression was performed to evaluate the association of study characteristics with the odds of TB treatment success. We selected a limited number of study characteristics to not overfit the model including: 1) study quality, 2) whether the study included individuals with MDR-TB, and 3) study setting. Study quality for studies was scored using the Newcastle Ottawa Scale (NOS); a summed score of 9–8 was categorized as a high-quality study; a summed score of 7–4 (inclusive) was categorized as a medium quality study, and a summed score of 3–0 (inclusive) was categorized as a low-quality study. Risk of bias assessments are summarized in S5 and S6 Tables. Qualitative analysis We reviewed qualitative manuscripts according to theme and content, and only included papers that described either TB treatment or socioeconomic outcomes. Findings are summarized in S2 Table. Risk of bias in individual studies We used the Cochrane Risk of Bias (RoB) tool [22] for RCTs and the Newcastle Ottawa Scale [23] (NOS) for all studies that quantitatively reported on outcomes. Studies are scored in 3 areas – selection (scored 0–4), comparability (scored 0–2), and outcome (scored 0–3), with higher scores indicating a positive assessment (less likely to be biased). Risk of bias was appraised by five researchers independently (MH, HT, AS, CC, PBS) (S5 and S6 Tables). Role of the funder Funding for this study comes from the Nina Ireland Program in Lung Health (PI: Shete, fund number 7710-138404-7504523-45). The funder of the study had no role in study design, data collection, data analysis, data interpretation, or writing of the report. Results After removing duplicates, we screened 55,975 titles and abstracts (Fig 1). After removing 55,880 articles based on title and abstracts, we evaluated 95 articles for eligibility. Forty-one articles did not meet our criteria for eligibility (S8 Table). Of the 55 included articles, 51 articles reported primarily on quantitative outcomes, while four articles reported only on qualitative outcomes [24–27]. The results of our search are reported in Fig 1 in accordance with PRISMA guidelines. Study characteristics including interventions, outcomes, and setting are summarized in S1-S4 Tables. Of the 51 articles that reported on quantitative outcomes, 42 (82.4%) were cohort studies, three studies (5.9%) were cross-sectional, one study (2%) was quasi-experimental, one (2%) was a randomized controlled trial, and four studies (7.8%) were cluster randomized trials. No studies were ecological. Studies were conducted across 18 different countries (S1 Table and S2 Table) and across urban, rural, and mixed settings (S1 & S2 Tables). Six different categories of social protection interventions were described in the studies that reported quantitative outcomes (S3 Table), with cash transfers (n = 25, 49%) being the most frequently described. Social protection interventions described in the qualitative studies reviewed (n = 4) included psychosocial, nutritional, and financial support in the form of transportation stipends. Interventions were described as either TB sensitive, e.g., eligibility criteria primarily pertaining to measures of poverty, or TB specific, for which only TB affected individuals and/or households were eligible. Thirty studies reported TB treatment success as the primary outcome of interest. Other outcomes included were mortality, TB treatment default (treatment interruption of at least two months [28], loss to follow up, treatment failure, or a combination of TB treatment outcomes (S4 Table) [29]. Eight studies reported primarily on socioeconomic outcomes, while two studies reported secondary socioeconomic outcomes (S4 Table). Five papers described how social protection reduced the risk of incurring catastrophic costs [3,30–33]. Wingfield et al., for example, found that a conditional cash transfer defrayed 20% of total costs, 39% of direct costs, and 19% of lost income. Among poorer households and female participants, the cash transfer defrayed total costs 22% and 23%, respectively [3]. Similarly, Florentino et al. found that social protection reduced catastrophic costs to a much greater extent among individuals with drug-resistant TB, who incurred higher costs than individuals with drug-susceptible TB [32]. As a secondary outcome, Li et al. found that expenses related to hospital admissions decreased as a result of social protection [34]. Three studies found that social protection did not improve outcomes, [35–37] while Liu et al. found that outpatient TB treatment outcomes improved with social protection while inpatient TB treatment outcomes were unchanged [38]. The majority of studies did not describe implementation process metrics, namely fidelity, reach, and coverage (S4 Table). Reasons for poor implementation fidelity reported by nine studies were related to administrative issues such as inadequate banking systems and/or delayed or non-disbursement of social protection benefits. Fidelity, coverage, or feasibility of social protection interventions was not consistently reported, which precluded analysis of implementation outcomes. Results of the risk of bias assessments are described in S5 Table and S6 Table. AS, CC, MH and PS used the Cochrane RoB Tool for Randomized studies, [22] and the NOS [39] to independently evaluate risk of bias in non-randomized studies that reported quantitatively on outcomes. We found the quality of the studies included to be high based on criteria specified in the Cochrane RoB tool and the NOS. Assessments of certainty and the quality of evidence of across studies were evaluated using the Grading of Recommendations, Assessment, Development, and Evaluation (GRADE) (further described in S9 Table). Random-effects meta-analysis was used for our primary outcome of interest, TB treatment success. Of the 33 studies that quantitatively reported on TB treatment success, two studies did not have a control group [38,40] and three studies did not report findings such that data could be extracted for meta-analysis calculations [41–43]. One study did not provide information about how the historical cohort was recruited and compared to the intervention cohort [44]. Lastly, although Wrohan et al. [45] reported treatment success by social health insurance status, researchers only evaluated one type of social health insurance as the “social protection intervention,” and did not include additional information about the cohort of individuals not using social health insurance. Authors of this meta-analysis agreed that there was not sufficient information provided in the study to distinguish the intervention from the control cohort. In addition, to optimize clarity, we have included S7 Table which summarizes the rationales for exclusion from the meta-analysis. We therefore included 26 studies in our meta-analysis. Lastly, one study included in the meta-analysis described how although a larger cohort of individuals was enrolled in a social protection intervention, only 233 individuals actually received the disbursed funds [46]. Authors therefore modified their analytic approach according to how many individuals actually received disbursed funds; [46] thus, we included only those who were enrolled and received the intervention in our meta-analysis. Studies that had a significant number of participants lost to follow up were scored accordingly in our risk of bias assessments (S5 Table and S6 Table). People with TB who were exposed to social protection interventions in conjunction with standard biomedical treatment had approximately two times the odds of achieving TB treatment success (Fig 2). The distribution of study effects is relatively narrow, with almost all studies reporting a positive effect. Our pooled estimate has an odds ratio of 2.15 (95% CI 1.76 to 2.64, p < .001), indicating that social protection was significantly associated with TB treatment success. However, the I2 of 94.49% suggests high between-study heterogeneity. Meta-analysis of treatment success rates in individuals who were enrolled and/or recipients of social protection vs. those who were not enrolled and/or recipients of a social protection intervention. Treatment = exposed to social protection, control = not exposed to social protection. The three RCTs included in the meta-analysis were Ismail et al. (2025), Reis-Santos et al., (2019) and Wingfield et al. (2017). To better characterize the range of true effects, we also reported the 95% prediction interval (OR 0.71- 6.53) (S1 Fig). The prediction interval indicates that on average across multiple studies, social protection increased the odds of TB treatment success, but the extent of the effect of social protection could range from null to substantial. The odds of TB treatment success were regressed on study covariates as shown in Table 1. Covariates were chosen based on previously published studies indicating that study quality, [47] inclusion of individuals with MDR-TB, [48] study setting, [9] and type of social protection [9] can influence the effect of an intervention. The results of our meta-regression indicated that conducting a study in a rural setting, the inclusion of MDR-TB, and a non-cash social protection intervention type were all not significantly associated with lower study odds of TB treatment success. Adjusting for other variables, the relationship between study quality and study odds ratio was not statistically significant; however, there was a trend for lower odds ratios of treatment success in high quality (-1.8 [-5.1, 1.6]) and medium quality (-2.3 [-7.4, 2.7]) studies compared to low quality studies. 10.1371/journal.pgph.0006704.t001Table 1Regression coefficients and p values from meta-regression of the study odds of TB treatment success across covariates of interest (n = 26).VariableRegression coefficient (95% CI)P valueStudy quality Low quality (reference)---- Medium quality-2.3 (-7.4, 2.7)0.3 High quality-1.8 (-5.1, 1.6)0.3Inclusion of individuals with MDR TB Yes1 (-1.5, 3.6)0.4 No0.8 (-1.8, 3.3)0.5Study setting Primarily rural-.2 (-5, 4.5)0.9 Mixed urban/rural-.4 (-3.3, 2.6)0.8 Primarily urban-.5 (-3.6, 2.5)0.7Social protection type Cash (reference)---- Nutrition.6 (-2.1, 3.4)0.6 Psychosocial-.1 (-2.8, 2.5)0.9 Mix of interventions.3 (-16, 2.3)0.7 Regression coefficients and p values from meta-regression of the study odds of TB treatment success across covariates of interest (n = 26). To evaluate the robustness of our findings and to elucidate the sources of heterogeneity, we conducted two additional types of analyses: 1) a leave-one-out sensitivity analysis, 2) subgroup analyses by intervention type, study setting, geographic region, and whether or not an intervention was TB specific or sensitive. Leave-one-out analysis (S2 Fig) suggests that high heterogeneity could not be attributed to a single study; the pooled estimate remained stable (2.05-2.25) and statistically significant across all analyses (p < .001 across all iterations). This finding suggests that the heterogeneity cannot be attributed to a single outlier study. Subgroup analysis by intervention type demonstrated that cash transfers, nutritional support, psychosocial support, and mixed interventions all increased the odds of TB treatment success (OR 1.95, 2.41, 2.23, and 2.41, respectively, p < .001 for all subgroups) (S3 Fig). However, the test for subgroup differences was not statistically significant (Qb(3)=1.75, p = 0.63), suggesting that the high heterogeneity across all studies could not be attributed to various types of social protection interventions. Similarly, study setting did not appear to be a source of heterogeneity (Qb(3)=0.84, p = 0.84), as social protection was associated with TB treatment success across primarily urban, primarily rural, and mixed settings (S4 Fig). There was significant variability in TB treatment success across different WHO regions (Qb(4)=11.57, p = 0.02), with pooled ORs ranging from 1.81 in the Americas to 4.25 in the European Region (S5 Fig). TB specific interventions had significantly higher odds of TB treatment success (OR 2.40, 95% CI 1.91 to 3.02) compared to TB sensitive programs (OR 1.43, 95% CI 1.04 to 1.95), and there was a statistically significant difference between the two subgroups (Qb(2)=6.98, p = 0.03) (S6 Fig). Four eligible studies utilized qualitative methods to describe the impact of social protection interventions. While the number of studies were too few to provide a meaningful content analysis, we identified themes across studies. Primarily, we evaluated qualitative studies according to type of social protection intervention and actual or perceived success or non-benefit of an intervention. We found that social protection interventions generally had high levels of acceptability among health care workers and people affected by TB, [24,25,49] and that interventions that offset the costs of direct non-medical costs related to TB enabled treatment adherence [49,50]. However, no studies explicitly evaluated potential negative perceptions or barriers to social protection. Discussion The results of this systematic review and meta-analysis provide a holistic assessment of the evidence available on the effectiveness of social protection interventions on TB treatment outcomes. Our search yielded 55 studies overall, including 26 studies eligible for a meta-analysis demonstrating that social protection interventions, when administered to individuals affected by TB and in conjunction with standard of care treatment, can double the odds of TB treatment success. This finding suggests that social protection interventions are associated with substantially improved TB treatment outcomes for TB affected individuals. While large seminal papers such as Jesus et al. (2025) [51] and Bhargava et al. (2023) [40] found that social protection can significantly reduce TB incidence and mortality, our systematic review highlights a larger body of evidence demonstrating that social protection can significantly improve TB treatment and socioeconomic outcomes. These results support the need to scale-up these programs globally in keeping with recent UN General Assembly High Level meeting commitments to the fight against TB which calls for all TB-affected individuals to have access to social protection interventions to prevent financial hardship by 2027 [7]. The findings of our meta-analysis, and our subsequently sub-group analysis, provide insight into the high variability across studies. While our pooled OR of 2.15 was relatively robust (95% CI 1.76 to 2.64, p < .001), this result represents an average effect across a wide range of studies that include different geographic settings, social protection interventions, and populations. Our leave-one-out analysis confirmed that no single study drove the variability, and that the pooled estimate was stable across each iteration of the analysis. However, the high heterogeneity and wide prediction interval, which better estimates the range of effects across different study settings and populations compared to the pooled OR, indicated that the magnitude of the benefit can range considerably across different contexts. This finding warranted further analysis to elucidate sources that drove heterogeneity. Our subgroup analyses revealed two sources of between-study heterogeneity. First, WHO region proved to be a significant source of between-study heterogeneity. These findings suggest that the magnitude of the effect of social protection can vary substantially given the sociodemographic features of a population, baseline TB epidemiology, and effective implementation of social protection interventions. Second, whether an intervention was TB specific or TB sensitive was also a significant source of between-study heterogeneity, with TB-specific programs conferring a much greater effect on TB treatment success. These findings parallel those by Ferreira et al. [52], and are perhaps the most significant in terms of health and social welfare policy. Albeit moderate, TB-sensitive social protection interventions still significantly improve the odds of TB treatment success, despite not being targeted specifically towards individuals with TB. Countries with existing, robust TB-sensitive interventions may consider interventions to ensure that TB-affected individuals have access to existing social protection interventions. TB specific interventions, which may be less costly, can confer a much greater benefit. National TB programs should consider incorporating social protection interventions to ensure higher rates of TB treatment success. Our findings demonstrated similar results to prior systematic reviews. For example, the 2018 study conducted by Richterman et al. [11] found that cash transfer interventions for TB-affected individuals was associated with 1.77 times the odds of a “positive TB treatment outcome.”11 The 2018 systematic review and meta-analysis by Andrade et al. found that participants who were beneficiaries of social protection interventions had 1.09 times the odds of TB treatment success and 1.11 times the odds of a cure compared to those who were not beneficiaries of social protection interventions [12]. While these prior studies are informative, we aimed to be more expansive and consistent in the definitions used for this review to align with global guidance on implementation of social protection for TB-affected households [53]. In particular, our analysis was based on current comprehensive definitions of social protection as endorsed by the World Bank and International Labor Organization (S3 Text) [5,54]. Although this search strategy yielded many articles that did not meet eligibility criteria, we captured studies that we may not have otherwise found with a narrower definition of social protection. Our subgroup analyses helped categorize these interventions by both type (cash transfer, food assistance) and whether the intervention was TB specific or sensitive. Our study also sought to estimate the potential impact of social protection interventions on reducing the risk of catastrophic and out-of-pocket costs among TB-affected households [3,24,30]. However, the types of socioeconomic outcomes reported on by eligible studies were variable and not comprehensive. For example, only five studies reported on the socioeconomic outcomes we specified in our search criteria; no studies reported on impoverishment measures. Although we aimed to provide a comprehensive assessment of the impact of social protection on socioeconomic outcomes, our outcomes of interest were underrepresented and insufficient to synthesize. The limitations of these findings highlight the need for standardizing socioeconomic outcomes for future studies in a manner that supports programmatic monitoring and evaluation of global indicators. Further, such findings would be key to developing person-and household centered approaches to developing and implementing social protection interventions to improve socioeconomic outcomes. Operational challenges to providing social protection feasibly and sustainably for TB-affected individuals have long been cited as a barrier for program coverage and uptake [55]. We analyzed eligible studies to inform operational and implementation outcomes including feasibility, coverage, or uptake. Unfortunately, the majority of studies did not describe these implementation outcomes or did not use standardized metrics (S4 Table). Of studies which reported implementation challenges, several describe administrative hurdles to provision of benefits; for example, unreliable banking systems resulting in delayed or failed disbursement of funds to beneficiaries and mitigating the potential impact of the intervention (S4 Table). Additional research to identify barriers and facilitators to accessing social protection, as well as standardizing and reporting implementation outcomes, would provide needed evidence on feasibility, acceptability, and coverage necessary to support the deployment, monitoring, and scale up of interventions. While the methods utilized in this systematic review, including robust risk of bias assessment and meta-regression, enhance our findings, our approach has limitations. The majority of studies that met eligibility criteria were from middle income settings, primarily Brazil, limiting generalizability of our findings; half of the high burden TB countries are located in Africa, are predominantly classified as low-income, and lack the robust landscape of existing social protection programs that Brazil has [28]. Second, the majority of studies reported cash transfer interventions. Additional evidence about other types of social protection interventions would be beneficial, especially as National TB Programs and other key stakeholders begin designing, implementing, and scaling up interventions. Lastly, because the majority of studies included in the meta-analysis were observational, we cannot exclude residual confounding. In conclusion, social protection interventions have the potential to significantly improve TB treatment outcomes. Our meta-analysis and subgroup analysis indicate that, on average, individuals who had access to social protection interventions had twice the odds of attaining TB treatment success compared to those who did not have access to social protection interventions. Our results, which are grounded in high quality evidence and robust to bias based on our meta-regression and subgroup analyses, indicate that a wide variety of social protection interventions can be considered to improve both TB treatment and socioeconomic outcomes. The standardized outcomes and definitions used in this systematic review and meta-analysis have the potential to guide further research on social protection programs for TB-affected populations. Patient and public involvement It was not appropriate or possible to involve patients or the public in the design, or conduct, or reporting, or dissemination plans of our research. Supporting information PICOT framework. (DOCX) Study team. (DOCX) Outcomes by PICOT. (DOCX) Search strategy keywords. (DOCX) Search strategies. (DOCX) Forest plot of the random-effects meta-analysis with 95% prediction interval. (TIF) Leave-one-out sensitivity analysis for the random-effects meta-analysis. (TIF) Subgroup analysis by intervention type. (TIF) Subgroup analysis by study setting. (TIF) Subgroup analysis by WHO region. (TIF) Subgroup analysis of TB sensitive and TB specific social protection interventions. (TIF) Study characteristics of quantitative studies (n = 51). (DOCX) Study characteristics of qualitative studies (n = 4). (DOCX) Social protection interventions described in quantitative studies (n = 51). (DOCX) Outcomes and implementation challenges described in quantitative studies (n = 46). (DOCX) Risk of bias assessments of non-randomized studies using the Newcastle Ottawa Scale (NOS). (DOCX) Risk of bias assessments of randomized controlled trials (RCTs) using the Cochrane Risk of Bias (RoB) assessment tool. (DOCX) Studies that reported on TB treatment success as the primary outcome of interest, but were not included in the meta-analysis. (DOCX) A listing of excluded studies (n = 40). (DOCX) GRADE assessment of certainty of evidence. (DOCX) Listing of all studies, both included and excluded, with reasons for exclusion if applicable. (DOCX) All extracted data from included studies. (XLSX) All extracted data required to conduct meta-analysis, meta-regression, and subgroup analyses. (XLSX) PRISMA Checklist. Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ 2021;372:n71. https://doi.org/10.1136/bmj.n71. Licensed under CC BY 4.0. To view a copy of this license, visit https://creativecommons.org/licenses/by/4.0/ (DOCX) 31 Mar 2026 Submitted filename: PLOS GPH Response to reviewers March.docx 23 Apr 2026 PGPH-D-26-01201 The impact of social protection interventions on treatment and socioeconomic outcomes of tuberculosis-affected people and households in low income, high burden settings: A systematic review and meta-analysis PLOS Global Public Health Dear Dr. Hudson, Thank you for submitting your manuscript to PLOS Global Public Health. After careful consideration, we feel that it has merit but does not fully meet PLOS Global Public Health’s publication criteria as it currently stands. Therefore, we invite you to submit a revised version of the manuscript that addresses the points raised during the review process. ============================== EDITOR: The reviewers have raised a number of concerns / issues to address with which I agree. Please take the time to consider these carefully. Also, note that both also congratulate you on an important manuscript and by-and-large sound approach. The required revisions are about being a bit more circumspect and critical. ============================== Please submit your revised manuscript by Jun 07 2026 11:59PM. If you will need more time than this to complete your revisions, please reply to this message or contact the journal office at globalpubhealth@plos.org. When you're ready to submit your revision, log on to https://www.editorialmanager.com/pgph/ and select the 'Submissions Needing Revision' folder to locate your manuscript file. Please include the following items when submitting your revised manuscript: A letter that responds to each point raised by the editor and reviewer(s). You should upload this letter as a separate file labeled 'Response to Reviewers'. A letter that responds to each point raised by the editor and reviewer(s). You should upload this letter as a separate file labeled 'Response to Reviewers'. A marked-up copy of your manuscript that highlights changes made to the original version. You should upload this as a separate file labeled 'Revised Manuscript with Track Changes'. A marked-up copy of your manuscript that highlights changes made to the original version. You should upload this as a separate file labeled 'Revised Manuscript with Track Changes'. An unmarked version of your revised paper without tracked changes. You should upload this as a separate file labeled 'Manuscript'. An unmarked version of your revised paper without tracked changes. You should upload this as a separate file labeled 'Manuscript'. Guidelines for resubmitting your figure files are available below the reviewer comments at the end of this letter. As the corresponding author, your ORCID iD is verified in the submission system and will appear in the published article. PLOS supports the use of ORCID, and we encourage all coauthors to register for an ORCID iD and use it as well. Please encourage your coauthors to verify their ORCID iD within the submission system before final acceptance, as unverified ORCID iDs will not appear in the published article. Only the individual author can complete the verification step; PLOS staff cannot verify ORCID iDs on behalf of authors. We look forward to receiving your revised manuscript. Kind regards, Graeme Hoddinott, Ph.D Academic Editor PLOS Global Public Health Journal Requirements: 1. As required by our policy on Data Availability, please ensure your manuscript or supplementary information includes the following: A numbered table of all studies identified in the literature search, including those that were excluded from the analyses. For every excluded study, the table should list the reason(s) for exclusion. If any of the included studies are unpublished, include a link (URL) to the primary source or detailed information about how the content can be accessed. A table of all data extracted from the primary research sources for the systematic review and/or meta-analysis. The table must include the following information for each study: Name of data extractors and date of data extraction Confirmation that the study was eligible to be included in the review. All data extracted from each study for the reported systematic review and/or meta-analysis that would be needed to replicate your analyses. If data or supporting information were obtained from another source (e.g. correspondence with the author of the original research article), please provide the source of data and dates on which the data/information were obtained by your research group. If applicable for your analysis, a table showing the completed risk of bias and quality/certainty assessments for each study or outcome. Please ensure this is provided for each domain or parameter assessed. For example, if you used the Cochrane risk-of-bias tool for randomized trials, provide answers to each of the signalling questions for each study. If you used GRADE to assess certainty of evidence, provide judgements about each of the quality of evidence factor. This should be provided for each outcome. An explanation of how missing data were handled. This information can be included in the main text, supplementary information, or relevant data repository. Please note that providing these underlying data is a requirement for publication in this journal, and if these data are not provided your manuscript might be rejected. 2. Please provide a detailed online Financial Disclosure statement. This is published with the article. It must therefore be completed in full sentences and contain the exact wording you wish to be published. a) State the initials, alongside each funding source, of each author to receive each grant. For example: “This work was supported by the National Institutes of Health (####### to AM; ###### to CJ) and the National Science Foundation (###### to AM).” b) State what role the funders took in the study. If the funders had no role in your study, please state: “The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.” For more information, please go to our submission guidelines: https://journals.plos.org/globalpublichealth/s/submission-guidelines#loc-financial-disclosure-statement 3. Please ensure that the funders and grant numbers match between the Financial Disclosure field and the Funding Information tab in your submission form. Note that the funders must be provided in the same order in both places as well. 4. Please update your online Competing Interests statement. If you have no competing interests to declare, please state: "The authors have declared that no competing interests exist." 5. Please provide separate main figure files in .tif or .eps format only and remove any figures embedded in your manuscript file. Please also ensure that all files are under our size limit of 10MB. Please leave the figure captions in the manuscript. For more information about how to convert your figure files please see our guidelines: https://journals.plos.org/globalpublichealth/s/figures 6. We notice that your supplementary materials are included in the manuscript file. Please remove them and upload them with the file type 'Supporting Information'. Please ensure that each Supporting Information file has a legend listed in the manuscript before or after the references list. 7. We have noticed that you have uploaded Supporting Information files, but you have not included a list of legends. Please add a full list of legends for your Supporting Information files before or after the references list. 8. If the reviewer comments include a recommendation to cite specific previously published works, please review and evaluate these publications to determine whether they are relevant and should be cited. There is no requirement to cite these works unless the editor has indicated otherwise. Additional Editor Comments (if provided): [Note: HTML markup is below. Please do not edit.] Reviewers' comments: Reviewer's Responses to Questions Comments to the Author 1. Does this manuscript meet PLOS Global Public Health’s publication criteria?> Reviewer #1: Yes Reviewer #2: Yes ********** 2. Has the statistical analysis been performed appropriately and rigorously?-->?> Reviewer #1: Yes Reviewer #2: Yes ********** 3. Have the authors made all data underlying the findings in their manuscript fully available (please refer to the Data Availability Statement at the start of the manuscript PDF file)??> The PLOS Data policy Reviewer #1: Yes Reviewer #2: Yes ********** 4. Is the manuscript presented in an intelligible fashion and written in standard English??> Reviewer #1: Yes Reviewer #2: Yes ********** Reviewer #1: This is a well-conducted and policy-relevant systematic review with important implications for TB control. However, substantial revisions are required to strengthen the interpretation of findings, address heterogeneity, and improve balance between outcomes before the manuscript is suitable for publication: 1) There is a very high heterogeneity (I²=94.5%) reported but it is insufficiently explored or interpreted. Authors should provide deeper investigation (subgroup analyses, sensitivity analyses) and clearer discussion of implications. 2) The conclusion that social protection “significantly improves” outcomes may be overstated given heterogeneity and predominance of observational studies. Authors are advised to give a more cautious and tempered down interpretation. 3) The manuscript is heavily skewed toward treatment outcomes, while socioeconomic outcomes are underrepresented and insufficiently synthesized. Authors should align with the stated objectives. 4) Key dimensions (coverage, fidelity, feasibility) are poorly reported and not systematically analyzed. Authors should expand discussion and highlight this gap more critically. 5) Variability in definitions of “social protection” and socioeconomic outcomes is acknowledged but not adequately operationalized. Authors should consider categorization or stricter inclusion criteria. 6) Could authors provide more details on how missing or non-extractable data was handled, how they decided which studies would be excluded from the meta-analysis, and the rationale for the meta-regression variable? 7) Although tools are applied, the implications of bias on pooled estimates are not critically discussed. could authors consider GRADE or clearer certainty of evidence framing? 8) Overrepresentation of middle-income settings (e.g. Brazil) limits applicability to low-income, high-burden African contexts. This should be more explicitly discussed and problematized 9) The introduction and discussion contain repetitive arguments regarding social protection importance. Please revise. 10) While policy relevance is mentioned, recommendations remain generic. Authors should provide more concrete, actionable guidance for TB programs. Reviewer #2: First, I would like to congratulate the authors for conducting a study on a highly timely and policy-relevant topic for global TB elimination, particularly in light of the increasing emphasis on social protection within strategies to end tuberculosis as a public health problem. The manuscript addresses an important and underexplored area and is based on a rigorous review process. I offer the comments below with the aim of clarifying some issues identified during reading and further strengthening the manuscript. In the Introduction, in the final paragraph, the manuscript refers to “systematic reviews” in the plural, although only one prior review is mentioned. Moreover, to the best of my knowledge, the existing body of evidence already includes previous systematic reviews, scoping reviews, and meta-analyses on the effects of TB-specific and TB-sensitive interventions implemented during TB treatment to provide social protection for people affected by TB. I would encourage the authors to engage more fully with this prior literature in order to better position the novelty and contribution of the present study, and to avoid unintentionally minimizing the state of the art already established on this topic. In the Methods section, I would also like to commend the authors for the methodological rigor of the review. The protocol registration, database coverage, and use of established risk-of-bias tools are all important strengths. However, I felt that the section would benefit from a short introductory paragraph clearly outlining the main stages of the systematic review and meta-analysis, especially for readers who may be less familiar with evidence synthesis methods. In addition, the decision to adopt the World Bank definition of social protection is valuable in terms of conceptual standardization, but it also introduces an important challenge: this definition brings together interventions of very different natures, including cash transfers, nutritional support, and psychosocial support. This degree of heterogeneity may affect the comparability of included studies and, consequently, the interpretation of the pooled estimates. I would encourage the authors to acknowledge this more explicitly, either in the Methods or in the Limitations. In the Results, one of the first points that draws attention, already from the abstract, is the very high heterogeneity reported in the meta-analysis (I² = 94.5%). While the use of a random-effects model is appropriate, I believe this degree of heterogeneity should be given greater prominence and interpreted more critically throughout the manuscript. In its current form, the statement that social protection interventions “significantly improve odds” of treatment success is statistically correct, but the magnitude and consistency of the pooled effect should be interpreted with caution given the substantial between-study variability. This issue deserves more explicit discussion, particularly in relation to whether the pooled estimate can reasonably be interpreted as a single overall effect across such diverse interventions and settings. Still in the Results, I found the analysis of socioeconomic outcomes somewhat underdeveloped. Although the number of studies reporting these outcomes was smaller and the measures were highly variable, this is one of the most innovative and policy-relevant dimensions of the review. The manuscript notes that only a limited number of studies assessed outcomes such as catastrophic costs and dissaving, but the narrative synthesis could be more analytically developed, especially because these outcomes are central to moving beyond a strictly biomedical understanding of TB and toward a person- and household-centered approach. In addition, the distinction between TB-specific and TB-sensitive social protection interventions is clearly introduced in the Methods, but this categorization is not explored comparatively in the Results or Discussion. I believe the manuscript would benefit from a more explicit analysis, since this distinction has important implications for policy design, implementation feasibility, and targeting in high-burden settings. Finally, in the Conclusion, and also in the section “How this study might affect research, practice or policy,” I felt there was room to strengthen the practical implications of the findings for the contexts highlighted by the study itself, namely low-income and high-burden settings. At present, the manuscript concludes that social protection improves treatment outcomes and may inform future implementation, but it says relatively little about what these findings imply for the design of future social protection programmes, how different intervention types might be prioritized, or what policymakers in high-burden settings can realistically take from the available evidence. A more explicit reflection on the operational and policy relevance of the findings would make the paper more useful for both researchers and decision-makers. ********** what does this mean?). If published, this will include your full peer review and any attached files. Do you want your identity to be public for this peer review? If you choose “no”, your identity will remain anonymous but your review may still be made public. For information about this choice, including consent withdrawal, please see our Privacy Policy Reviewer #1: No Reviewer #2: Yes: Melisane Regina Lima Ferreira ********** [NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link "View Attachments". If this link does not appear, there are no attachment files.] 4 Jun 2026 Submitted filename: Responses to PLOS GPH 4 June 2026.docx 9 Jul 2026 PGPH-D-26-01201R1 The impact of social protection interventions on treatment and socioeconomic outcomes of tuberculosis-affected people and households in low income, high burden settings: A systematic review and meta-analysis PLOS Global Public Health Dear Dr. Hudson, Thank you for submitting your manuscript to PLOS Global Public Health. After careful consideration, we feel that it has merit but does not fully meet PLOS Global Public Health’s publication criteria as it currently stands. Therefore, we invite you to submit a revised version of the manuscript that addresses the points raised during the review process. ============================== EDITOR: As suggested by reviewers, just a few minor changes requested. ============================== Please submit your revised manuscript by Aug 08 2026 11:59PM. If you will need more time than this to complete your revisions, please reply to this message or contact the journal office at globalpubhealth@plos.org. When you're ready to submit your revision, log on to https://www.editorialmanager.com/pgph/ and select the 'Submissions Needing Revision' folder to locate your manuscript file. Please include the following items when submitting your revised manuscript: A letter that responds to each point raised by the editor and reviewer(s). You should upload this letter as a separate file labeled 'Response to Reviewers'. A letter that responds to each point raised by the editor and reviewer(s). You should upload this letter as a separate file labeled 'Response to Reviewers'. A marked-up copy of your manuscript that highlights changes made to the original version. You should upload this as a separate file labeled 'Revised Manuscript with Track Changes'. A marked-up copy of your manuscript that highlights changes made to the original version. You should upload this as a separate file labeled 'Revised Manuscript with Track Changes'. An unmarked version of your revised paper without tracked changes. You should upload this as a separate file labeled 'Manuscript'. An unmarked version of your revised paper without tracked changes. You should upload this as a separate file labeled 'Manuscript'. Guidelines for resubmitting your figure files are available below the reviewer comments at the end of this letter. As the corresponding author, your ORCID iD is verified in the submission system and will appear in the published article. PLOS supports the use of ORCID, and we encourage all coauthors to register for an ORCID iD and use it as well. Please encourage your coauthors to verify their ORCID iD within the submission system before final acceptance, as unverified ORCID iDs will not appear in the published article. Only the individual author can complete the verification step; PLOS staff cannot verify ORCID iDs on behalf of authors. We look forward to receiving your revised manuscript. Kind regards, Graeme Hoddinott, Ph.D Academic Editor PLOS Global Public Health Journal Requirements: If the reviewer comments include a recommendation to cite specific previously published works, please review and evaluate these publications to determine whether they are relevant and should be cited. There is no requirement to cite these works unless the editor has indicated otherwise. Please review your reference list to ensure that it is complete and correct. If you have cited papers that have been retracted, please include the rationale for doing so in the manuscript text, or remove these references and replace them with relevant current references. Any changes to the reference list should be mentioned in the rebuttal letter that accompanies your revised manuscript. If you need to cite a retracted article, indicate the article’s retracted status in the References list and also include a citation and full reference for the retraction notice. Additional Editor Comments (if provided): [Note: HTML markup is below. Please do not edit.] Reviewers' comments: Reviewer's Responses to Questions Comments to the Author Reviewer #1: All comments have been addressed Reviewer #2: All comments have been addressed ********** publication criteria?> Reviewer #1: Yes Reviewer #2: Yes ********** 3. Has the statistical analysis been performed appropriately and rigorously?-->?> Reviewer #1: Yes Reviewer #2: Yes ********** 4. Have the authors made all data underlying the findings in their manuscript fully available (please refer to the Data Availability Statement at the start of the manuscript PDF file)??> The PLOS Data policy Reviewer #1: Yes Reviewer #2: Yes ********** 5. Is the manuscript presented in an intelligible fashion and written in standard English??> Reviewer #1: Yes Reviewer #2: Yes ********** Reviewer #1: The authors have addressed all major concerns adequately. There are only minor polish ups left, before acceptance for publication: 1) Some grammatical errors need to be corrected: social protection inventions should be interventions; were generally had high levels should be generally had high levels; amount individuals should be among individuals; statically significant should be statistically significant; literately developed should be iteratively developed. Please do a final language proofreading and editing. 2) The abstract reports 26 studies in the meta-analysis, but the results section reports 24 studies and then later in the meta-regression you report 26; please authors correct this and be consistent. 3) the wording " can dramatically improve TB treatment outcomes" is an overstatement; it is best replaced by "are associated with substantially improved treatment outcomes". 4) in the discussion briefly mention residual confounding in observational studies, publication bias if funnel plot/egger's test was assessed and finally why prediction intervals are more informative than pooled ORs when heterogeneity is high. Reviewer #2: Thank you to the authors for the careful revision. The manuscript has improved substantially, particularly through the more explicit discussion of heterogeneity. I also particularly appreciate the subgroup comparison between TB-specific and TB-sensitive interventions, which adds important policy relevance to the study. Overall, I believe the main substantive concerns have been adequately addressed. I only have a few minor comments for final revision: In the Methods, the sentence stating that "studies describing type of intervention were not included" (line 175) is unclear and seems inconsistent with the rest of the manuscript, since intervention types were included and analyzed later. This likely needs rewording. In the Results, "intervention type" (line 337) is listed twice in the description of subgroup analyses. There is an inconsistency in the number of studies included in the meta-analysis: the abstract and Table 2 indicate 26 studies, while the Results section states 24 studies. Please check and correct this throughout the manuscript. The citation "Lima Ferriera et al." should be corrected to "Ferreira et al.". Congratulations! ********** what does this mean?). If published, this will include your full peer review and any attached files. Do you want your identity to be public for this peer review? If you choose “no”, your identity will remain anonymous but your review may still be made public. For information about this choice, including consent withdrawal, please see our Privacy Policy Reviewer #1: No Reviewer #2: No ********** [NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link "View Attachments". If this link does not appear, there are no attachment files.] Figure Resubmissions: 28 Jul 2026 Submitted filename: V2 Plos response to reviewers 28 July 2026.pdf 30 Jul 2026 The impact of social protection interventions on treatment and socioeconomic outcomes of tuberculosis-affected people and households in low income, high burden settings: A systematic review and meta-analysis PGPH-D-26-01201R2 Dear Dr. Hudson, We are pleased to inform you that your manuscript 'The impact of social protection interventions on treatment and socioeconomic outcomes of tuberculosis-affected people and households in low income, high burden settings: A systematic review and meta-analysis' has been provisionally accepted for publication in PLOS Global Public Health. Before your manuscript can be formally accepted you will need to complete some formatting changes, which you will receive in a follow up email. A member of our team will be in touch with a set of requests. Please note that your manuscript will not be scheduled for publication until you have made the required changes, so a swift response is appreciated. IMPORTANT: The editorial review process is now complete. PLOS will only permit corrections to spelling, formatting or significant scientific errors from this point onwards. Requests for major changes, or any which affect the scientific understanding of your work, will cause delays to the publication date of your manuscript. If your institution or institutions have a press office, please notify them about your upcoming paper to help maximize its impact. If they'll be preparing press materials, please inform our press team as soon as possible -- no later than 48 hours after receiving the formal acceptance. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information, please contact globalpubhealth@plos.org. Thank you again for supporting Open Access publishing; we are looking forward to publishing your work in PLOS Global Public Health. Best regards, Graeme Hoddinott, Ph.D Academic Editor PLOS Global Public Health *********************************************************** Reviewer Comments (if any, and for reference): Reviewer's Responses to Questions Comments to the Author Reviewer #1: All comments have been addressed Reviewer #2: All comments have been addressed ********** publication criteria?> Reviewer #1: Yes Reviewer #2: Yes ********** 3. Has the statistical analysis been performed appropriately and rigorously?-->?> Reviewer #1: Yes Reviewer #2: Yes ********** 4. Have the authors made all data underlying the findings in their manuscript fully available (please refer to the Data Availability Statement at the start of the manuscript PDF file)??> The PLOS Data policy Reviewer #1: Yes Reviewer #2: Yes ********** 5. Is the manuscript presented in an intelligible fashion and written in standard English??> Reviewer #1: Yes Reviewer #2: Yes ********** Reviewer #1: No further comments. Authors have addressed all concerns adequately Reviewer #2: (No Response) ********** what does this mean?). If published, this will include your full peer review and any attached files. Do you want your identity to be public for this peer review? If you choose “no”, your identity will remain anonymous but your review may still be made public. For information about this choice, including consent withdrawal, please see our Privacy Policy Reviewer #1: No Reviewer #2: Yes: Melisane Regina Lima Ferreira **********